Records kept by the federal Drug Enforcement Administration show that 76 billion oxycodone and hydrocodone pills—the vast majority of them generics, not brand names—were shipped to U.S. pharmacies from 2006 to 2012.
Recovery chain with checkered history plans to open Indy treatment center
Recovery Centers of America, based in Pennsylvania, had been temporarily shut down in Massachusetts over concerns regarding patient care and safety. It is now planning to open its first Indiana treatment center.Read More
Groups protest insulin prices outside Lilly headquarters
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.Read More
Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.Read More
Fast-growing Activate Healthcare acquired by Denver firm
The Indianapolis-based provider of health clinics for businesses has grown to 250 employees in 10 years. But it recently started looking for another owner.Read More
The trial in Oklahoma City is the first of more than 1,900 local U.S. government lawsuits against drug makers and distributors over the fallout from opioid abuse.
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
The nonpartisan Congressional Budget Office estimated the plan would have little impact on manufacturer prices and cost Medicare $177 billion over 10 years by leading to higher premiums subsidized by taxpayers.
Lilly shares dropped 4.6 percent in early trading after the company said Christi Shaw was leaving and Mike Harrington planned to retire.
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
The fate of former President Barack Obama's signature health care law, and its coverage and insurance protections for millions of Americans, is again being argued in a case that appears destined for the Supreme Court.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Should you avoid red meat? No. Should you strive for 10,000 steps a day? Not unless you just want to. So says Dr. Aaron Carroll, a pediatrician and researcher at the Indiana University School of Medicine who sees it as his life’s calling to debunk what he considers health myths and weak medical research.
Ryan Kitchell oversees a wide variety of business operations at the state’s largest health system. His departure comes as IU Health is in the midst of numerous capital projects.
Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Insurers said the idea could backfire, prompting hospitals that now give deeper discounts to try to raise their own negotiated prices to match what high earners are getting. Hospitals were skeptical of the move.
The federal regulations Trump is calling for would push forward a relatively simple idea: that patients should know how much hospitals charge for common procedures.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The Louisville-based company expects to invest more than $52 million to launch its Indiana operations at the River Ridge Commerce Center in Jeffersonville.
The American Medical Association Opioid Task Force 2019 Progress Report shows Indiana's reduction in opioid prescriptions from 2013 to 2018 is two percentage points higher than the national average.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”